Anthony P Heaney

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi request reprint Novel pituitary ligands: peroxisome proliferator activating receptor-gamma
    Anthony P Heaney
    Division of Endocrinology, Cedars Sinai Research Institute, Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Pituitary 6:153-9. 2003
  2. ncbi request reprint Pituitary tumour pathogenesis
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Br Med Bull 75:81-97. 2005
  3. ncbi request reprint PPAR-gamma in Cushing's disease
    Anthony P Heaney
    Division of Endocrinology, Cedars Sinai Research Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Pituitary 7:265-9. 2004
  4. ncbi request reprint Molecular targets in pituitary tumours
    Anthony P Heaney
    Cedars Sinai Research Institute, 8700 Beverly Blvd, Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Nat Rev Cancer 4:285-95. 2004
  5. pmc PPAR-gamma receptor ligands: novel therapy for pituitary adenomas
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Invest 111:1381-8. 2003
  6. ncbi request reprint Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    Nat Med 8:1281-7. 2002
  7. ncbi request reprint Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells
    Anat Ben-Shlomo
    Division of Endocrinology and Metabolism, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:858-63. 2003
  8. pmc Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease
    Li Du
    Department of Medicine and Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 110:8555-60. 2013
  9. ncbi request reprint Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas
    Manory A Fernando
    Division of Endocrinology, B 127, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Mol Endocrinol 19:3085-96. 2005
  10. ncbi request reprint Fructose induces transketolase flux to promote pancreatic cancer growth
    Haibo Liu
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90024, USA
    Cancer Res 70:6368-76. 2010

Research Grants

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Novel pituitary ligands: peroxisome proliferator activating receptor-gamma
    Anthony P Heaney
    Division of Endocrinology, Cedars Sinai Research Institute, Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Pituitary 6:153-9. 2003
    ....
  2. ncbi request reprint Pituitary tumour pathogenesis
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Br Med Bull 75:81-97. 2005
    ..The interplay between genetic and humoural factors to promote cellular transformation is exemplified in pituitary tumorigenesis and is discussed in this review...
  3. ncbi request reprint PPAR-gamma in Cushing's disease
    Anthony P Heaney
    Division of Endocrinology, Cedars Sinai Research Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Pituitary 7:265-9. 2004
    ....
  4. ncbi request reprint Molecular targets in pituitary tumours
    Anthony P Heaney
    Cedars Sinai Research Institute, 8700 Beverly Blvd, Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Nat Rev Cancer 4:285-95. 2004
  5. pmc PPAR-gamma receptor ligands: novel therapy for pituitary adenomas
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Invest 111:1381-8. 2003
    ..TZDs are proposed as novel oral medications for managing pituitary tumors...
  6. ncbi request reprint Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    Nat Med 8:1281-7. 2002
    ..Based on these findings, thiazolidinediones may be an effective therapy for Cushing disease..
  7. ncbi request reprint Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells
    Anat Ben-Shlomo
    Division of Endocrinology and Metabolism, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:858-63. 2003
    ..These observations indicate a role for LIF in loss of autocrine PRL suppression contributing to unrestrained prolactinomas PRL secretion. Moreover, PRL suppression by LIF may be mediated by gp130 and D2R interaction...
  8. pmc Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease
    Li Du
    Department of Medicine and Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 110:8555-60. 2013
    ..Our findings directly link TR4 to the etiology of corticotroph tumors, hormone secretion, and cell growth as well as identify it as a potential target in the treatment of CD...
  9. ncbi request reprint Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas
    Manory A Fernando
    Division of Endocrinology, B 127, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Mol Endocrinol 19:3085-96. 2005
    ..dox is proposed as a possible novel medical therapy for pituitary tumors...
  10. ncbi request reprint Fructose induces transketolase flux to promote pancreatic cancer growth
    Haibo Liu
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90024, USA
    Cancer Res 70:6368-76. 2010
    ..They have major significance for cancer patients given dietary refined fructose consumption, and indicate that efforts to reduce refined fructose intake or inhibit fructose-mediated actions may disrupt cancer growth...
  11. ncbi request reprint The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis
    Hongxiang Hui
    Division of Endocrinology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90024, USA
    Eur J Cancer 44:160-6. 2008
    ..Doxazosin is proposed as a possible novel medical therapy for breast cancer...
  12. ncbi request reprint Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression
    Gregory A Horwitz
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    Mol Endocrinol 17:600-9. 2003
    ..These results indicate that targeting PTTG1-mediated signaling alters the hormonal phenotype in pituitary cells and disrupted PTTG1 action may be a potential subcellular therapeutic tool for repressing PRL hypersecretion...
  13. ncbi request reprint The pituitary stalk effect: is it a passing phenomenon?
    Marvin Bergsneider
    Department of Neurosurgery, David Geffen School of Medicine at UCLA, Gonda 3357, Box 951761, Los Angeles, CA, 90095 1761, USA
    J Neurooncol 117:477-84. 2014
    ..In males, the hyperprolactinemia window is more likely to be missed clinically due to an absence of prolactin-related symptoms...
  14. doi request reprint Targeting pituitary tumors
    Anthony P Heaney
    Division of Endocrinology and Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, Calif, USA
    Horm Res 68:132-6. 2007
    ....
  15. pmc Fructose impairs glucose-induced hepatic triglyceride synthesis
    Danshan Huang
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Lipids Health Dis 10:20. 2011
    ..These studies provide novel insight into the mechanisms involved in fructose-mediated hepatic hypertriglyceridemia and identify fructose-uptake as a new potential therapeutic target for lipid-associated diseases...
  16. ncbi request reprint Securin is overexpressed in breast cancer
    Selam Ogbagabriel
    Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA, USA
    Mod Pathol 18:985-90. 2005
    ..We propose immunohistochemical tumor securin expression as a potential invasive marker, and novel therapeutic target in breast cancer...
  17. doi request reprint Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature
    Run Yu
    Division of Endocrinology, Cedars Sinai Medical Cente, Los Angeles, CA 90048, USA
    Pancreas 36:428-31. 2008
    ..Nesidioblastosis and hyperplasia of alpha cells should be considered in the differential diagnosis of hyperglucagonemia. Somatostatin analog may be used to suppress glucagon secretion in alpha-cell hyperplasia...
  18. doi request reprint Pituitary function in patients with normal pressure hydrocephalus before and after neurosurgical correction
    Tannaz Moin
    Department of Medicine, Veterans Affairs of Greater Los Angeles, David Geffen School of Medicine, University of California, Los Angeles, California 90073, USA
    J Clin Endocrinol Metab 97:3545-9. 2012
    ..We also sought to ascertain whether surgical correction of hydrocephalus would result in improvement of any noted pituitary dysfunction...
  19. ncbi request reprint Refined fructose and cancer
    Haibo Liu
    University of California, David Geffen School of Medicine, Division of Endocrinology, Departments of Medicine and Neurosurgery, Los Angeles, CA 90024, USA
    Expert Opin Ther Targets 15:1049-59. 2011
    ..Caloric excess, including increased refined carbohydrate intake, is associated with higher cancer risk emphasizing the importance of improved understanding of cancer cell metabolism in tumor survival and metastasis...
  20. pmc Functional role of estrogen in pituitary tumor pathogenesis
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    J Clin Invest 109:277-83. 2002
    ....
  21. doi request reprint Acromegaly due to an ectopic pituitary adenoma in the clivus: case report and review of literature
    Julia Goulart Appel
    Department of Medicine, David Geffen School of Medicine at UCLA, 9 240 N Factor Building, Los Angeles, CA 90095, USA
    Pituitary 15:S53-6. 2012
    ..The epidemiology and pertinent literature of this uncommon condition is discussed...
  22. pmc Regulation of adipose differentiation by fructose and GluT5
    Li Du
    David Geffen School of Medicine, Division of Endocrinology, 9240 P Factor Building, Los Angeles, California 90095, USA
    Mol Endocrinol 26:1773-82. 2012
    ..Taken together, these results demonstrate that fructose and GluT5 play an important role in regulating adipose differentiation...
  23. doi request reprint Bilateral adrenalectomy: lifesaving procedure in severe Cushing syndrome
    Jennifer Y Han
    Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, USA
    Endocr Pract 18:e85-90. 2012
    ..To discuss the role of bilateral adrenalectomy in Cushing syndrome, as illustrated in a case of severe hypercortisolism that was unresponsive to combination agent medical therapy...
  24. pmc Clinical review: Pituitary carcinoma: difficult diagnosis and treatment
    Anthony P Heaney
    Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, USA
    J Clin Endocrinol Metab 96:3649-60. 2011
    ..Diagnosis is difficult, resulting in delays that may adversely effect outcome that is traditionally poor. Barriers to earlier diagnosis and management strategies for pituitary carcinoma are discussed...
  25. ncbi request reprint Direct spectrophotometric determination of serum fructose in pancreatic cancer patients
    Hongxiang Hui
    Division of Endocrinology, David Geffen School of Medicine at UCLA, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA 90024, USA
    Pancreas 38:706-12. 2009
    ..We sought to develop an assay to measure circulating fructose concentrations in pancreatic cancer patients...
  26. ncbi request reprint Temozolomide: a novel treatment for pituitary carcinoma
    Stephen Lim
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Lancet Oncol 7:518-20. 2006
  27. ncbi request reprint Pituitary tumour transforming gene in endocrine cancer
    Chris J McCabe
    Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK
    Clin Endocrinol (Oxf) 58:673-82. 2003

Research Grants3

  1. Chemoprevention of Pituitary Corticotroph Tumors
    Anthony Heaney; Fiscal Year: 2006
    ..Our ultimate goal is to develop a rationale for clinical application of these PPAR-gamma ligands as a novel medical therapy in Cushing's disease. ..
  2. Refined Fructose Promotes Pancreatic Cancer Growth
    Anthony Heaney; Fiscal Year: 2007
    ..Our identification of GLUT-5 as a key in the molecular mechanism by which pancreatic cancer cells preferentially utilize fructose may pave the way to novel therapeutic approaches targeting GLUT-5 action in pancreatic cancer. ..
  3. ROSIALITAZONE: NOVEL THERAPY FOR PITUITARY TUMORS (PHAS*
    Anthony Heaney; Fiscal Year: 2007
    ..A complete response will be defined as normalization of urinary cortisol levels in the Cushing's patients, and disappearance of pituitary tumors in the non-secreting tumors from baseline. ..